EUVIMEDEUVIMED entdecken
Crossref

Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival”

Veronica Conca iD, Daniele Rossini iD, Chiara Cremolini iD

Journal of Clinical Oncology · 10.08.2026 · 44 (23) · 2255-2257

DOI: 10.1200/jco-26-00870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2026. Verfasst von Veronica Conca und 2 weiteren Autor:innen. Beteiligte Einrichtung: Veronica Conca, MD, PhD, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Department of Translational Research and …. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Veronica Conca, MD, PhD, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Ital…

ORCID-Profile: Veronica Conca, Daniele Rossini, Chiara Cremolini

Zitieren

APA

Conca, V., Rossini, D., & Cremolini, C. (2026). Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival”. Journal of Clinical Oncology, 44(23), 2255-2257. https://doi.org/10.1200/jco-26-00870

Vancouver

Conca V, Rossini D, Cremolini C. Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival”. Journal of Clinical Oncology. 2026;44(23):2255-2257. doi:10.1200/jco-26-00870

BibTeX
@article{Conca2026,
  author = {Conca, Veronica and Rossini, Daniele and Cremolini, Chiara},
  title = {Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival”},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {23},
  pages = {2255--2257},
  doi = {10.1200/jco-26-00870}
}
Kostenlos starten →